Understanding Blenrep

Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the combination of a monoclonal antibody (mAb) that binds to a specific receptor on the surface of myeloma cells called B-cell maturation antigen (BCMA), coupled with monomethyl auristatin F (MMAF), a drug that can kill myeloma cells.

BCMA is involved in myeloma cell growth and survival, and is found on the surface of cells in all patients with myeloma. When the monoclonal antibody portion of Blenrep attaches to BCMA, Blenrep enters the cell and releases MMAF, which leads to cell death. The antibody part of the ADC attracts your body’s own immune system to recognize the cancerous myeloma cells and attack them.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.